MONIQUE CARASSO: Open Payments
NPI 1992835581 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,124 in 46 payments from 8 companies in 2025. Trend: 2023 $374 · 2024 $737 · 2025 $1,124
Food & beverage: $1,124
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 25 | $397 |
| Madrigal Pharmaceuticals | 5 | $285 |
| Ipsen Biopharmaceuticals, Inc | 5 | $164 |
| Gilead Sciences, Inc. | 5 | $122 |
| ORPHALAN INC | 2 | $49 |
| Intercept Pharmaceuticals, Inc. | 2 | $45 |
| ABBVIE INC. | 1 | $33 |
| Mirum Pharmaceuticals, Inc. | 1 | $28 |
Products named: XIFAXAN, REZDIFFRA, IQIRVO, CUVRIOR, OCALIVA, LINZESS, Livmarli.
Industry payments across NY — which companies pay providers there.
